Centessa Pharmaceuticals plc
CNTA
Clasificación en acciones
#2960
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Precio por acción
$40.50
Última sincronización: 2026-06-29
Capitalización bursátil
$6.22B
Cambio (1 día)
0.00%
Cambio (1 año)
77.71%
País
GB
Comercio Centessa Pharmaceuticals plc (CNTA)
Categoría
Healthcare
Ratio P/E de Centessa Pharmaceuticals plc (CNTA)
Ratio P/E al October 2026 TTM: -22.75
Según los últimos informes financieros y el precio de las acciones de Centessa Pharmaceuticals plc, el P/E actual (TTM) de la empresa es -22.75. Al final de 2023, la empresa tenía un P/E de -5.07.
Historial del ratio P/E de Centessa Pharmaceuticals plc desde 2019 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | -22.75 | 179.86% |
| 2024 | -8.13 | 60.50% |
| 2023 | -5.07 | 278.38% |
| 2022 | -1.34 | -98.59% |
| 2021 | -95.03 | -34.28% |
| 2020 | -144.60 | -67.01% |
| 2019 | -438.27 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | -226.50% |
US
|
|
| -28.36 | 24.64% |
US
|
|
| -24.57 | 7.97% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -233.30% |
NL
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.